Mersana Therapeutics, Inc. (MRSN)

Market Cap	67.93M
Revenue (ttm)	34.84M
Net Income (ttm)	-74.62M
Shares Out	123.53M
EPS (ttm)	-0.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,727,937
Open	0.630
Previous Close	0.619
Day's Range	0.548 - 0.630
52-Week Range	0.548 - 6.280
Beta	1.42
Analysts	Buy
Price Target	6.00 (+991.11%)
Earnings Date	Feb 26, 2025

About MRSN

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in Nove...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 28, 2017
• Employees: 123
• Stock Exchange: NASDAQ
• Ticker Symbol: MRSN
• Website: https://www.mersana.com

Financial Performance

In 2023, Mersana Therapeutics's revenue was $36.86 million, an increase of 38.65% compared to the previous year's $26.58 million. Losses were -$171.67 million, -15.94% less than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for MRSN stock is "Buy." The 12-month stock price forecast is $6.0, which is an increase of 991.11% from the latest price.

Price Target

$6.0

(991.11% upside)

Analyst Consensus: Buy